Excerpt From Conference Call Regarding QTinno and it's potential once the market returns.
"As it relates to this commercial ramp for QTinno™, our initial target is Phase 1 QT studies. This market was affected disproportionately in terms of the
cutback in spending on clinical trials by drug sponsors, but we believe that our
business model has put us in a prime position to capture market share as the
Phase 1 studies return. In fact, we are optimistic that we may experience a bit of an acceleration due to the backlog of Phase 1 studies that were postponed but now must be performed to effectively define compounds’ cardiac safety profile as it moves through the drug sponsors’ pipeline."
"The presentation of how our technology demonstrates superiority in accuracy of key cardiac safety metrics as well as the potential to advance cardiac safety analysis through the development of new cardiac safety markers by Dr. Gussak, our Chief Medical Officer, led to a number of qualified leads for QTinno™. Accordingly, there is a growing market acceptance, most certainly, as evidenced by our announcements last week. So, at this point in time, it is a matter of the Phase 1 market returning to the pre-2009 levels of activity and potentially more, if you consider the pent-up demand from those studies that had been on hold. We believe, given our current and potential customer footprint, that as the market returns, we will be ideally positioned to capture a significant portion of that activity. As we stated eloquently at the end of the debate (sp?) referenced earlier, the industry must understand that the science and technology continues to advance and, as such, must be prepared to embrace those advances as they are proven to be validated and reliable."
On the return of the market....
"What we’re seeing is that Request for Proposals (RFPs) are coming out, and they’re starting to talk about it, and you’re seeing the timelines of late Q4, first half of 2011."
